These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34322859)

  • 1. Pulmonary function impairment of asymptomatic and persistently symptomatic patients 4 months after COVID-19 according to disease severity.
    Munker D; Veit T; Barton J; Mertsch P; Mümmler C; Osterman A; Khatamzas E; Barnikel M; Hellmuth JC; Münchhoff M; Walter J; Ghiani A; Munker S; Dinkel J; Behr J; Kneidinger N; Milger K
    Infection; 2022 Feb; 50(1):157-168. PubMed ID: 34322859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal Analysis of Pulmonary Function Impairment One Year Post-COVID-19: A Single-Center Study.
    Suppini N; Fira-Mladinescu O; Traila D; Motofelea AC; Marc MS; Manolescu D; Vastag E; Maganti RK; Oancea C
    J Pers Med; 2023 Jul; 13(8):. PubMed ID: 37623441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follow-Up Analysis of Pulmonary Function, Exercise Capacity, Radiological Changes, and Quality of Life Two Months after Recovery from SARS-CoV-2 Pneumonia.
    Strumiliene E; Zeleckiene I; Bliudzius R; Samuilis A; Zvirblis T; Zablockiene B; Strumila A; Gruslys V; Malinauskiene L; Kasiulevicius V; Jancoriene L
    Medicina (Kaunas); 2021 Jun; 57(6):. PubMed ID: 34204878
    [No Abstract]   [Full Text] [Related]  

  • 4. Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae.
    Daher A; Balfanz P; Cornelissen C; Müller A; Bergs I; Marx N; Müller-Wieland D; Hartmann B; Dreher M; Müller T
    Respir Med; 2020; 174():106197. PubMed ID: 33120193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent pulmonary abnormalities after 18 months of SARS-CoV-2 pneumonia.
    Valenzuela C; de la Fuente L; Hernández S; Olivera MJ; Molina C; Montes N; Benavides C; Caballero P
    Radiologia (Engl Ed); 2024 Apr; 66 Suppl 1():S47-S56. PubMed ID: 38642961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-fourth of COVID-19 patients have an impaired pulmonary function after 12 months of disease onset.
    van Willigen HDG; Wynberg E; Verveen A; Dijkstra M; Verkaik BJ; Figaroa OJA; de Jong MC; van der Veen ALIP; Makowska A; Koedoot N; Nieuwkerk PT; Boyd A; Prins M; de Jong MD; de Bree GJ; van den Aardweg JG;
    PLoS One; 2023; 18(9):e0290893. PubMed ID: 37695755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of factors impairing exercise capacity after severe COVID-19 pulmonary infection: a 3-month follow-up of prospective COVulnerability cohort.
    Ribeiro Baptista B; d'Humières T; Schlemmer F; Bendib I; Justeau G; Al-Assaad L; Hachem M; Codiat R; Bardel B; Abou Chakra L; Belmondo T; Audureau E; Hue S; Mekontso-Dessap A; Derumeaux G; Boyer L
    Respir Res; 2022 Mar; 23(1):68. PubMed ID: 35317815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary Function, Computed Tomography Lung Abnormalities, and Small Airway Disease after COVID-19: 3-, 6-, and 9-Month Follow-Up.
    Kłos K; Jaskóła-Polkowska D; Plewka-Barcik K; Rożyńska R; Pietruszka-Wałęka E; Żabicka M; Kania-Pudło M; Maliborski A; Plicht K; Angielski G; Wojtyszek A; Jahnz-Różyk K; Chciałowski A
    J Clin Med; 2024 May; 13(10):. PubMed ID: 38792275
    [No Abstract]   [Full Text] [Related]  

  • 9. Abnormal exercise adaptation after varying severities of COVID-19: A controlled cross-sectional analysis of 392 survivors.
    Braga F; Domecg F; Kalichsztein M; Nobre G; Kezen J; Espinosa G; Prado C; Facio M; Moraes G; Gottlieb I; Lima RL; Danielian A; Emery MS
    Eur J Sport Sci; 2023 May; 23(5):829-839. PubMed ID: 35306969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of clinical symptoms, radiological changes and pulmonary function data 4 months after COVID-19.
    Labarca G; Henríquez-Beltrán M; Lastra J; Enos D; Llerena F; Cigarroa I; Lamperti L; Ormazabal V; Ramirez C; Espejo E; Canales N; Fuentes F; Horta G; Fernandez-Bussy S; Nova-Lamperti E
    Clin Respir J; 2021 Sep; 15(9):992-1002. PubMed ID: 34086416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual symptoms, lung function, and imaging findings in patients recovering from SARS-CoV-2 infection.
    Darawshy F; Abu Rmeileh A; Kuint R; Padawer D; Karim K; Fridlender Z; Laxer U; Goychman Cohen P; Berkman N
    Intern Emerg Med; 2022 Aug; 17(5):1491-1501. PubMed ID: 35235130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional limitations 12 months after SARS-CoV-2 infection correlate with initial disease severity: An observational study of cardiopulmonary exercise capacity testing in COVID-19 convalescents.
    Steinbeis F; Knape P; Mittermaier M; Helbig ET; Tober-Lau P; Thibeault C; Lippert LJ; Xiang W; Müller-Plathe M; Steinbrecher S; Meyer HJ; Ring RM; Ruwwe-Glösenkamp C; Alius F; Li Y; Müller-Redetzky H; Uhrig A; Lingscheid T; Grund D; Temmesfeld-Wollbrück B; Suttorp N; Sander LE; Kurth F; Witzenrath M; Zoller T
    Respir Med; 2022 Oct; 202():106968. PubMed ID: 36081267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Investigation of Pulmonary Function Changes of COVID-19 Patients in Three Months.
    Ye L; Yao G; Lin S; Fang Y; Chen X; Wang L; He S
    J Healthc Eng; 2022; 2022():9028835. PubMed ID: 35047158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-field MRI lung opacity severity associated with decreased DLCO in post-acute Covid-19 patients.
    Azour L; Segal LN; Condos R; Moore WH; Landini N; Collazo D; Sterman DH; Young I; Ko J; Brosnahan S; Babb J; Chandarana H
    Clin Imaging; 2024 Nov; 115():110307. PubMed ID: 39383681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual pulmonary infiltrates, symptoms and diffusion impairment at 1-year after severe COVID-19 infection have different associated factors.
    Menéndez R; Méndez R; Latorre A; González-Jiménez P; Peces-Barba G; Molina M; España PP; García E; Consuegra-Vanegas A; Pando-Sandoval A; Panadero C; Figueira-Gonçalves JM; De la Rosa D; Sibila O; Martínez-Pitarch MD; Toledo N; Cejudo P; Almonte-Batista W; Macías-Paredes A; Badenes D; Pérez-Rodas EN; Lázaro J; Quirós S; Cordovilla R; Cano-Pumarega I; Torres A;
    J Intern Med; 2023 Jul; 294(1):69-82. PubMed ID: 37038609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary function tests in the follow-up of children with COVID-19.
    Öztürk GK; Beken B; Doğan S; Akar HH
    Eur J Pediatr; 2022 Jul; 181(7):2839-2847. PubMed ID: 35522314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cluster analysis unveils a severe persistent respiratory impairment phenotype 3-months after severe COVID-19.
    Perotin JM; Gierski F; Bolko L; Dury S; Barrière S; Launois C; Dewolf M; Chouabe S; Bongrain E; Picard D; Tran E; N'Guyen Y; Mourvillier B; Servettaz A; Rapin A; Marcus C; Lebargy F; Kaladjian A; Salmon JH; Deslee G
    Respir Res; 2022 Aug; 23(1):199. PubMed ID: 35918719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study.
    Guler SA; Ebner L; Aubry-Beigelman C; Bridevaux PO; Brutsche M; Clarenbach C; Garzoni C; Geiser TK; Lenoir A; Mancinetti M; Naccini B; Ott SR; Piquilloud L; Prella M; Que YA; Soccal PM; von Garnier C; Funke-Chambour M
    Eur Respir J; 2021 Apr; 57(4):. PubMed ID: 33419891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of Real Time PCR Cycle Threshold Values in Symptomatic and Asymptomatic COVID-19 Patients].
    Gülbudak H; Karvar Ş; Soydan G; Tezcan Ülger S; Kandemir Ö; Tamer L; Altunkan AA; Özdemir AA; Aslan G
    Mikrobiyol Bul; 2021 Jul; 55(3):435-444. PubMed ID: 34416808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.